Biocon Gains Over 1% as Subsidiary Signs Settlement and License Deal with Amgen
Mumbai (Udaipur Kiran News): Shares of Biocon Ltd rose over 1.6% in Wednesday’s trading session after its subsidiary, Biocon Biologics, signed a settlement and license agreement with Amgen Inc. paving the way for the commercial launch of its biosimilar drugs Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States. The stock was trading at ₹346.35, … Read more
